Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
Report highlights significant improvements in adolescent well-being in India
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Subscribe To Our Newsletter & Stay Updated
